Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3065863 | Journal of Neuroimmunology | 2007 | 7 Pages |
Abstract
Ganglioside complexes (GSCs) are known as target antigens in Guillain–Barré syndrome (GBS). To elucidate the clinical importance of the anti-GSC antibodies in GBS, we investigated serum antibodies to GSCs containing two of the gangliosides, GM1, GD1a, GD1b and GT1b, and analyzed clinical features of anti-GSC-positive GBS patients. Thirty-nine (17%) of 234 GBS patients had IgG anti-GSC antibodies. Anti-GSC-positive GBS had antecedent gastrointestinal infection and lower cranial nerve deficits more frequently than control GBS. The presence of antibody specificity to GD1a/GD1b and/or GD1b/GT1b was significantly associated with severe disability and a requirement for mechanical ventilation.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
K. Kaida, D. Morita, M. Kanzaki, K. Kamakura, K. Motoyoshi, M. Hirakawa, S. Kusunoki,